BURKITT LYMPHOMA

This study looks at how well doctors follow treatment guidelines for children with Burkitt lymphoma, a fast-growing cancer. Researchers will track 1,000 children across Africa to see if early detection and tailored treatment can improve survival. The goal is to refine care for di…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests a stem cell transplant method for people under 25 with certain blood cancers. The approach filters out specific immune cells from donated stem cells to lower the risk of graft-versus-host disease (a serious complication) while helping the new cells grow. Up to 40…

This study tests a new drug called pidnarulex (CX-5461) in people with certain fast-growing lymphomas linked to the MYC gene. The goal is to find a safe dose and see if it can shrink tumors. About 50 adults who have already tried other treatments will take part.

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This early-phase trial is testing whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain aggressive lymphomas. About 25 adults with high-risk features will receive up to 6 cycles of trea…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people whose B-cell lymphoma has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and how well it works. Pa…

This study is for children under 25 who have had a stem cell transplant for blood cancers like leukemia. After transplant, their immune system is weak, putting them at high risk for dangerous infections. Researchers are adding back a specific type of donor cell (CD45RA-depleted) …

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to improve cancer remissi…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…